SanBio logo

SanBio(OTC) SNBIF

Market Cap$789.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)+19%
5 Year-28%
1 Year-29%
1 Month+0%
$10.11
+0.00%
+0.00Today
SanBio last closing stock price
MetricPriceDate
Last closeUSD 10.112026-07-15
SanBio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 10.112026-07-06
1 month+0%USD 10.112025-12-30
3 month+0%USD 10.112025-12-30
Year to date+0%USD 10.112025-12-30
1 year-29.2%USD 14.282025-07-15
3 year+83.82%USD 5.502023-01-23
5 year-28.14%USD 14.072021-06-08
Since inception+18.94%USD 8.502015-10-12

SanBio Financials at a Glance

Market Cap

$789.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥0.00

Net Income (TTM)

-¥3.64B

EPS (TTM)

-$0.31

P/E Ratio

-33.04

Dividend

$0.00

Beta (Volatility)

-0.15 (Low)

Price

$10.11

Volume

42,433

Open

$10.11

Previous Close

$10.11

Daily Range

$10.11 - $10.11

52-Week Range

$10.11 - $23.00

Estimated Earnings Date

Dec 15, 2026

SNBIF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SanBio

SanBio Company Limited is a biopharmaceutical firm focused on developing regenerative cell therapies for central nervous system disorders. The company is known for its innovative product SB623, which has shown promise in treating traumatic brain injury and is advancing research for various other conditions.

Products and Services
  • SB623 for traumatic brain injury and other neurological conditions
  • SB618 targeting peripheral nerve damage
  • SB308 for muscular dystrophy and MSC1 for cancer treatment
Growth Outlook
  • Strong pipeline with multiple therapies in various stages of clinical trials
  • Focus on expanding applications of SB623 beyond traumatic brain injury
  • Potential market growth driven by increasing demand for regenerative therapies
Financial Highlights
  • Recent quarterly net income of -834.7 million JPY, reflecting ongoing R&D investments
  • Cash and cash equivalents of 12.7 billion JPY, providing a solid financial cushion
  • Current ratio of 39.4, indicating strong liquidity and financial health
SanBio Company Limited is positioned in the biotechnology sector, specializing in regenerative medicine. The company has made significant strides with its lead product, SB623, which has completed Phase 2 clinical trials in both the U.S. and Japan. This product's potential to address traumatic brain injury and other neurological disorders places SanBio at the forefront of innovative healthcare solutions. The growth outlook for SanBio is promising, with a robust pipeline that includes therapies for various conditions, such as Parkinson's disease and spinal cord injuries. The increasing global demand for regenerative therapies further supports the company's potential for expansion and market penetration. Financially, SanBio has maintained a strong liquidity position, with substantial cash reserves that allow for continued investment in research and development. Despite recent net losses, the company's current ratio indicates a healthy balance sheet, which is crucial for sustaining operations and funding future projects. Overall, SanBio Company Limited presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in the realm of regenerative medicine.
AI Generated • Sep 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

33

CEO

Keita Mori, MBA

Website

www.sanbio.com

Headquarters

Tokyo, TY 104-0044, JP

SNBIF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-37.79%

Return on Capital

-25.57%

Return on Assets

-26.65%

Earnings Yield

-3.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$789.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

78.06M

Volume

42.43K

Avg. Volume

652.815

Financials (TTM)

Gross Profit

-¥8.23M

Operating Income

-¥3.82B

EBITDA

-¥3.68B

Operating Cash Flow

¥0.00

Capital Expenditure

¥0.00

Free Cash Flow

¥0.00

Cash & ST Invst.

¥12.75B

Total Debt

¥1.13B

SanBio Performance Analysis

SanBio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-01-31JPY 0N/A
20242024-01-31JPY 0N/A
20252025-01-31JPY 0N/A
20262026-01-31JPY 0N/A
SanBio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-31N/A
Q42026-01-31N/A
Q12026-04-30N/A
Q22026-07-31N/A
SanBio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-01-31JPY -0.72-11.3%
20242024-01-31JPY -0.29-60.6%
20252025-01-31JPY -0.27-3.7%
20262026-01-31JPY -0.3527.8%
SanBio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-31-54.2%
Q42026-01-31-48.7%
Q12026-04-3027.8%
Q22026-07-31-14.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2027YOY CHG

Revenue

¥0.00

N/A

Gross Profit

¥0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$789.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$23.91M

N/A

Employees

33

N/A

Net Income

-¥954.96M

-105.1%

EBITDA

-¥942.16M

-7.2%

Quarterly Fundamentals

Name
Q2 2027YOY CHG

Total Cash

¥12.75B

+365.5%

Total Debt

¥1.13B

-17.0%

Accounts Receivable

¥0.00

N/A

Inventory

¥142.71M

N/A

Long Term Debt

¥1.13B

+3.0%

Short Term Debt

¥0.00

-100.0%

Return on Assets

-26.65%

N/A

Return on Invested Capital

-28.68%

N/A

Free Cash Flow

¥0.00

N/A

Operating Cash Flow

¥0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,803.85-0.00%
^DJIDJI
$51,687.96-0.00%
^IXICNASDAQ
$27,201.84-0.00%
BTCBitcoin
$83,069.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$50.96-5.56%
CRWVCoreWeave
$65.23-16.17%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$41.49+10.86%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$114.09-10.57%

Questions About SNBIF

What is the current price of SanBio?

SanBio is trading at $10.11 per share.

What is the 52-week range for SanBio?

Over the past 52 weeks, SanBio has traded between $10.11 and $23.00.

How much debt does SanBio have?

As of the most recent reporting period, SanBio reported total debt of ¥7.07M.

How much cash does SanBio have on hand?

SanBio reported ¥80.06M in cash and cash equivalents in its most recent financial results.

What is SanBio’s dividend yield?

SanBio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services